- VIVEbiotech has launched EvoLVcell, a stable producer cell line platform for lentiviral vector manufacturing designed to reduce variability and improve scalability.
- The platform is intended to provide a transfection-free alternative to transient transfection processes and support long-term lentiviral vector production strategies.
VIVEbiotech has announced the launch of EvoLVcell, a stable producer cell line platform designed to support lentiviral vector manufacturing for gene therapy applications.
The company stated that EvoLVcell provides a transfection-free alternative to transient transfection processes currently used in lentiviral vector production. According to VIVEbiotech, the platform incorporates a characterised inducible monoclonal lentiviral packaging cell line intended to simplify manufacturing workflows, reduce batch-to-batch variability, and improve long-term production predictability.
VIVEbiotech said the platform is designed to reduce dependence on plasmid and transfection reagent supply chains while improving vector quality and lowering contaminants associated with manufacturing. The company added that the system allows developers to generate a prototype stable cell line within three months and supports both adherent and suspension manufacturing platforms.
“Achieving cost efficiency and high reproducibility is essential for the scalable production of lentiviral vectors and for expanding patient access. EvoLVcell provides a powerful alternative to transient transfection — one that de-risks production, improves quality, and supports long-term scalability for our partners.”
Andrés Lamsfus-Calle, PhD, Product Development Manager at VIVEbiotech.
The company stated that EvoLVcell will initially support VSV-G pseudotyped lentiviral vectors and will complement its existing transient transfection capabilities. VIVEbiotech said the new platform expands its CDMO and contract manufacturing offering for developers working on gene therapy programmes requiring scalable lentiviral vector production.
